Compare Repligen Corporation Common Stock (RGEN) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs VanEck Semiconductor ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while VanEck Semiconductor ETF trades at $553.92 (market cap $71.21B). The key difference: VanEck Semiconductor ETF is far larger — about 6.4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and VanEck Semiconductor ETF for 102 Days on average.
| RGEN | SMH | |
|---|---|---|
Market Cap | $11.14B | $71.21B |
Volume | 1,259,263 | 7,965,961 |
Sector | Health | — |
52-Week High | $194.57 | $668.91 |
52-Week Low | $102.87 | $325.10 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SMH, the VanEck Semiconductor ETF, trades at $564.74, down 4.44% over 24 hours amid sector volatility. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while RSI_6 at 26.18 suggests potential oversold conditions. Recent news highlights strong 2026 performance, with the ETF up around 69% year-to-date, outpacing major holdings like Nvidia, and benefiting from AI-driven semiconductor demand and industry consolidation such as AMD's acquisition of World Labs.
The outlook for SMH remains positive due to robust sector growth and AI expansion, though risks include high concentration in top holdings and sensitivity to tech sector swings. Investors should weigh the ETF's historical outperformance against potential volatility from trade tensions and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
